Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Bill Retains ANDA “Antibundling” Language “Livable” To GPhA

Executive Summary

Medicare prescription drug benefit legislation is likely to contain a modified version of the House bill's "antibundling" provision for generic drug applications following a Sept. 30 Capitol Hill meeting between the brand and generic drug industries
Advertisement

Related Content

GlaxoSmithKline Hires Former FDA Top Lawyer Dan Troy As General Counsel
GlaxoSmithKline Hires Former FDA Top Lawyer Dan Troy As General Counsel
FDA Guidance On ANDA Antibundling Statute Expected In February
FDA Guidance On ANDA Antibundling Statute Expected In February
Paxil Generics On Hold After Court Rejects FDA “Shared Exclusivity” Policy
Generic Rx Reforms: No Automatic “Controversy” For Declaratory Judgments
FDA First-Generic Notification Policy May Be Reviewed
Medicare Rx Discount Card Will Pass Congress This Fall – HHS’ Thompson
Generic Rx Delays Could Result From House Medicare Provisions, GPhA Says
Generic Rx Delays Could Result From House Medicare Provisions, GPhA Says
Advertisement
UsernamePublicRestriction

Register

PS042577

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel